Back to Agenda
Session 6: Operational Considerations
Session Chair(s)
Craig H Lipset, MPH
Managing Partner
Clinical Innovation Partners, United States
Daniel Millar, MBA
Senior Director, Strategic Business Transformation
Johnson & Johnson, United States
Getting a master protocol trial started may seem daunting. How do you go from an impressive theoretical design to a tangible trial? And how do you convince internal stakeholders that it will be operationally feasible within your constraints? This session will explore best practices for master protocol operationalization. Experienced industry colleagues will share their insights on setting up and operating master protocols, including assessment of internal capabilities and practical approaches to resolving common problems. An interactive expert panel and time for question and answer will round out the session.
Speaker(s)
Operational Considerations for Master Protocols: Experience in GBM AGILE
Meredith Buxton, PhD, MPH
Global Coalition For Adaptive Research, United States
Chief Executive Officer
Operational Considerations: Janssen’s Platform Trial in Evaluating Novel Compounds in Crohn’s Disease
Yichuan Xia, PhD
Johnson&Johnson, United States
Director
Moderator
Daniel Millar, MBA
Johnson & Johnson, United States
Senior Director, Strategic Business Transformation
Panelist
Victoria Manax Rutson, MD
Pancreatic Cancer Action Network, United States
Chief Medical Officer
Panelist
Lisa LaVange, PhD
University of North Carolina at Chapel Hill, United States
Professor Emerita
Have an account?